

Big data analysis for setup margin personalization derived from intra-fraction motion: a proof of concept

SGRT Community Annual Meeting

December 1st, 2023

M. Gonod¹ (mgonod@cgfl.fr), L. Delcoudert¹, S. Morisset²,
V. Robineau¹, J. Farah³, L. Aubignac¹, I. Bessières¹

¹ Centre Georges François Leclerc (CGFL) - Dijon

² Independent biostatistician

³ Vision RT Ltd. Dove House. Arcadia Avenue London - United Kingdom



unicancer BOURGOGNE FRANCHE-COMTÉ


visionrt

 **CGFL**
CENTRE GEORGES
FRANÇOIS LECLERC
Ensemble, dépassons le cancer

TABLE 2.1—Factors to be considered when defining a planning target volume

Category	Intrafractional variations (Variations during a single fraction)		Interfractional variations (Variations during the entire course of treatment)	
	Random	Systematic	Random	Systematic
Variations of CTV				
In size	Physiological processes (circulation, respiration, peristalsis)	Physiological processes (circulation)	Physiological processes (e.g., degree of bladder filling, bowel gas)	Tumor reduction or swelling
In position relative to a fixed point in the patient	Physiological processes (circulation, respiration, peristalsis)	Change in treatment position (prone-supine)	Physiological processes (e.g., degree of filling of cavities)	Weight loss
Variations in position of the patient relative to the treatment beams	Patient movements		Daily set-up	Technical errors

Introduction



• PTV margin

• ICRU 50/62

- Combination of factors
- Leading to a hypothetical coverage of the CTV

- Hypothesis example of Van Herk 2000 : achieve a minimum dose of 95% of the prescribed dose on the CTV for 90% of patients

• PTV margin is a sum or combination of different factors

• ICRU recommendations : Factors have to be evaluated when it's possible

- By statistical assessment
- By qualitative assessment when statistics are not applicable

• All factors are probably can be independently estimated

• PTV margin is contained between 0 and the sum of all of the maximum of each independent factors

• The reduction of PTV margins is a major challenge in the reduction of radiotherapy-related toxicities

Today PTV margin is standardized by location, dose, ...
 From recommendations / guidelines / trials
 Most of cases : No patient or machine individualization

Part of PTV due to Intra Fraction Motion = PTV_{IFM}

PTV margin



- Surface information

- AlignRT → Measures intra-fraction external motion
- Reported in RTD files (translations, rotations, time, ... 70 different informations)
- Data of patient motion available

→ Amplitude = f(time)

→ Amplitude histogram → Representative value


A screenshot of a data table with multiple columns and rows, representing patient motion data. The table is highlighted with a red border.



● Mean
 Standard dev
 Max
 ...

- Histogram of maximal amplitude of the motion by fraction for a patient
- And for all fraction of all patient

- Cumulative histogram
- Histogram of the motion for all your patient
- Width of the histogram of the maximal intra fraction motion by fraction for all patients = $2 \times PTV_{IFM}$



- **PTV**


- Width of the histogram of the maximal intra fraction motion by fraction for all patients = $2 \times PTV_{IFM}$
- Comparison patient by patient
 - Amplitude of maximal motions for a patient is less than the total amplitude

→ PTV_{IFM} is too large for any patient ? So total PTV margin is too large too ?

Amplitude measured for our patients = $2 \times PTV_{IFM}$


- Patient 1
- Patient 2
- Patient 3
- Patient 4
- Patient 5

Amplitude




Amplitude of $2 \times PTV_{IFM_Patient_X}$ measured for each patients

Frequency



Position in the global histogram



- Patient 1
- Patient 2
- Patient 3
- Patient 4
- Patient 5


Amplitude measured for our patients = $2 \times PTV_{IFM}$

- PTV

- Width of the histogram of the maximal intra fraction motion by fraction for all patients = $2 \times PTV_{IFM}$
- Comparison patient by patient
 - Amplitude of maximal motions for a patient is less than the total amplitude

→ PTV_{IFM} is too large for any patient ? So total PTV margin is too large too ?

Amplitude measured for our patients = $2 \times PTV_{IFM}$



$$PTV_{Clinical_Used} = PTV_{AllOtherFactors} + PTV_{IFM}$$

$$PTV_{Real_Patient_X} = PTV_{AllOtherFactors} + PTV_{IFM_Patient_X}$$

- BUT** the PTV margins have to be defined before treatment planning


→ Is it possible to predict these $PTV_{IFM_Patient_X}$?

→ Is it possible to predict patient intra fraction motion ?


→ Is there a correlation between IFM and clinical / technical data exists ?

- Database

- 379 patients / 501 plans / 5599 fractions – August 2020 to august 2021 (No lungs or mediastinals / No masks)
 - 50 clinical and technical data → ARIA and Manual extraction
 - AlignRT Measurements → RTD extraction
 - MAG value between the beginning of the 1st beam to the end of the last one
- PTV hypothesis = The patient have to be in good place for 95% of the time
- Representative value for each fraction Z define by the Amplitude of IFM for 95% of time divided by 2





- Correlation between clinical/technical and IFM
 - Conditionnal Inference Tree (CIT) : Big data – Machine learning tool
 - Separate the database into the 2 most statistically different parts using only 1 clinical parameter
 - Restart the same separation for each new node



CIT Configuration :

- Library partykit v1.2-16
- Level of significance 5%
- Node stage limit 5
- Session limit by group 100




Number of sessions
 Number of plans = $N_{p_{node}}$
 Histogram of Z

- Made for 3 groups of PTV margin : 10 mm; 7-8 mm; 5 mm

- Predictivity test

- Cross validation : 4 equal parts with random patient/session
 - 4 different models with 75% of the population
 - Model test with the remaining 25% of the population


Database			
P1	P2	P3	P4
25%	25%	25%	25%



- 2 tests with hypothesis of validation :
 - Patient : The patient have a real Z_{MAX} less than or equal to the predicted Z_{MAX} ?
 - Session : The session have a real Z_{MAX} less than or equal to the predicted Z_{MAX} ?

- PTV_{IFM} histogram reconstruction

- For each node, the histogram of Z value have been ranged by millimeter [0;1[, [1;2[, [2;3[, [3;4[, [4;5[, [5;max[.
- The number of plans for each node have been associated in the range of the maximal value of Z in the node



Z_{max}	[0;1[[1;2[[2;3[[3;4[[4;5[[5;max[
Node 1			Np_{node_1}			
...						
Node x					Np_{node_X}	
Sum by column						
Relative						

- $PTV_{Real_Patient_X}$ calculation

Standardised PTV margin

$$PTV_{Clinical_Used} = PTV_{AllOtherFactors} + PTV_{IFM}$$

Maximal measured IFM for all patient


$$PTV_{AllOtherFactors} = PTV_{Clinical_Used} - PTV_{IFM}$$

$$PTV_{Real_Patient_X} = PTV_{AllOtherFactors} + PTV_{IFM_Patient_X}$$

Individualized PTV margin

Maximal predicted IFM for this patient

- Correlation between clinical/technical and IFM
 - 1094 sessions with missing data → Out of model
 - CIT result (PTV 10 mm) : 2795 sessions – 10 groups
 - CIT result (PTV 7-8 mm) : 1374 sessions – 5 groups
 - CIT result (PTV 5 mm) : 336 sessions – 2 groups



- Predictivity test

- Cross validation – Method 1 : Proportion of patient that have a real Z_{MAX} less than or equal to the predicted Z_{MAX} ?

Cross validation n°	% of true result
1	97.8
2	98.4
3	98.9
4	98.3

(mean ± std) : (98.4 ± 0.5)%


- Cross validation – Method 2 : Proportion of session that have a real Z_{MAX} less than or equal to the predicted Z_{MAX} ?

Cross validation n°	% of true result
1	83.9
2	82.6
3	83.3
4	81.1

(mean ± std) : (82.7 ± 0.5)%

- PTV_{IFM} histogram reconstruction

node	N_plans	[0-1[[1-2[[2-3[[3-4[[4-5[[5-max[
10	62				62		
11	25						25
12	17					17	
14	14			14			
17	11			11			
18	8	8					
19	32						32
6	29				29		
7	41				41		
9	11				11		
0	0						
0	0						
Somme plan par catégorie	Absolu	0	8	25	143	17	57
	Relatif	0,0%	3,2%	10,0%	57,2%	6,8%	22,8%



- PTV_{Real_Patient_X} calculation

- 5 mm PTV margin : can't be individualized
- 7-8 mm PTV margin : 55.6% of margins can't be individualized but 44.4% can have a reduction of 2.2 mm
- 10 mm PTV margin : Margin individualisation usefull for 77.2% of patient.

PTV 10 mm	[0;1[[1;2[[2;3[[3;4[[4;5[[5;max[
% of patient	0.0	3.2	10.0	57.2	6.8	22.8
Possible PTV individualized (mm)	5.22	6.22	7.22	8.22	9.22	10
Possible PTV win (mm)	4.78	3.78	2.78	1.78	0.78	0

- Discussion

- PTV hypothesis choice : 100% of patient & 95% of time

- Uncertainties combination for PTV margin calculation

$$PTV_{Clinical_Used} = PTV_{AllOtherFactors} + PTV_{IFM} ?$$

- MAG is the most representative value for PTV ?



- We have to go to test for combinaison of 3 measured translations

MAG ? → VRT, LNG, LAT

- Z is representative ?

- Take into account starting position and movement trend

- CIT algorithm seems to be good but we didn't evaluate others




- Conclusion

- Correlation between IFM and clinical / technical information exists
- IFM can be predicted using this correlation
- PTV margins can be individualized for 62% of our patients on this database
- Prediction can be verified at each fraction using AlignRT information

➔ Reduction of the toxicities

➔ Verification with a clinical trial ?

- Have to be include in AlignRT ?



“All truth passes through three stages. - First. it is ridiculed. - Second. it is violently opposed. - Third. it is accepted as being self-evident”

Apocryphal citation of Arthur Schopenhauer

Big data analysis for setup margin personalization derived from intra-fraction motion: a proof of concept

SGRT Community Annual Meeting
December 1st, 2023

Thank you for your attention

M. Gonod (mgonod@cgfl.fr), L. Delcoudert¹, S. Morisset²,
V. Robineau¹, J. Farah³, L. Aubignac¹, I. Bessières¹

¹ Centre Georges François Leclerc (CGFL) - Dijon

² Independent biostatistician

³ Vision RT Ltd. Dove House. Arcadia Avenue London - United Kingdom



unicancer BOURGOGNE FRANCHE-COMTÉ

visionrt

 **CGFL**
CENTRE GEORGES
FRANÇOIS LECLERC
Ensemble, dépassons le cancer